Mixed amphetamine salts: Difference between revisions

Nav

(View all pending changes)

[checked revision]

← Older edit Newer edit →

VisualWikitext

@@ Line 34: / Line 34: @@
 '''Narcolepsy:''' 5–60 mg/day in divided doses.
 '''Renal/hepatic impairment:''' caution; reduce dose. Avoid in severe renal impairment.
-| effects           = ''Therapeutic:'' improved attention and executive function, reduced impulsivity and hyperactivity, increased wakefulness, mild euphoria, increased motivation, mild appetite suppression.
+| effects           = | effects =
-''Common adverse:'' decreased appetite (often dose-limiting), insomnia, dry mouth, irritability, anxiety, mild elevation of heart rate and blood pressure, headache, jaw clenching/bruxism, mild weight loss.
-| adverse           = * '''Cardiovascular:''' tachycardia, hypertension, palpitations; rare but reported cases of sudden cardiac death in patients with structural heart disease (FDA warning)
+==== Therapeutic ====
-* '''Psychiatric:''' anxiety, agitation, insomnia, irritability; rarely psychosis or mania (especially in patients with bipolar predisposition)
+* <effect slug="attention" label="Attention and focus">Improved attention, executive function, and working memory.</effect>
-* '''Dependence and misuse''' — Schedule II controlled substance; high abuse liability, particularly when crushed/insufflated/injected
+* <effect slug="reduced-impulsivity" label="Reduced impulsivity and hyperactivity"/>
-* '''Tolerance''' to therapeutic effects can develop with chronic high-dose use
+* <effect slug="wakefulness" label="Wakefulness"/>
-* '''Growth suppression''' in children — modest reduction in height/weight velocity with chronic stimulant use
+* <effect slug="motivation" label="Motivation and drive"/>
-* '''Serotonin syndrome''' — especially in combination with serotonergic agents or MAOIs
+* <effect slug="euphoria" label="Mild euphoria"/>
-* '''Stereotyped behaviors''' (skin-picking, repetitive movements) at higher doses
-* '''Bruxism and TMJ symptoms'''
+==== Common ====
-* '''Peripheral vasculopathy''' — Raynaud-like phenomenon, rare digital ischemia
+* <effect slug="decreased-appetite" label="Decreased appetite">Often dose-limiting; may produce weight loss over time.</effect>
-* '''Lowered seizure threshold''' (caution in epilepsy)
+* <effect slug="insomnia" label="Insomnia">Especially with late-afternoon dosing.</effect>
-* '''Hyperthermia''' — risk in hot environments or with vigorous exercise
+* <effect slug="dry-mouth" label="Dry mouth"/>
-* '''Withdrawal''' on abrupt discontinuation — fatigue, depression, hypersomnia, increased appetite ("crash")
+* <effect slug="irritability" label="Irritability"/>
+* <effect slug="anxiety" label="Anxiety"/>
+* <effect slug="hr-bp-elevation" label="Elevated heart rate / blood pressure">Usually mild but dose-dependent.</effect>
+* <effect slug="headache" label="Headache"/>
+* <effect slug="bruxism" label="Jaw clenching / bruxism">May produce TMJ symptoms over time.</effect>
+* <effect slug="weight-loss" label="Weight loss"/>
+==== Cardiovascular ====
+* <effect slug="palpitations" label="Palpitations"/>
+* <effect slug="cardiac-event" label="Serious cardiac event">Rare reports of sudden cardiac death in patients with structural heart disease (FDA warning).</effect>
+==== Psychiatric ====
+* <effect slug="agitation" label="Agitation"/>
+* <effect slug="psychosis" label="Psychosis">Rare; higher risk in patients with bipolar predisposition.</effect>
+* <effect slug="mania" label="Mania">Rare; higher risk in patients with bipolar predisposition.</effect>
+==== Other adverse ====
+* <effect slug="dependence" label="Dependence / misuse">Schedule II controlled substance; high abuse liability, particularly when crushed, insufflated, or injected.</effect>
+* <effect slug="tolerance" label="Tolerance">To therapeutic effects, with chronic high-dose use.</effect>
+* <effect slug="growth-suppression" label="Growth suppression">Modest reduction in height/weight velocity in chronically-treated children.</effect>
+* <effect slug="serotonin-syndrome" label="Serotonin syndrome">Especially in combination with serotonergic agents or MAOIs.</effect>
+* <effect slug="stereotypies" label="Stereotyped behaviors">Skin-picking, repetitive movements at higher doses.</effect>
+* <effect slug="vasculopathy" label="Peripheral vasculopathy">Raynaud-like phenomenon, rare digital ischemia.</effect>
+* <effect slug="seizure" label="Lowered seizure threshold">Caution in epilepsy.</effect>
+* <effect slug="hyperthermia" label="Hyperthermia">Risk in hot environments or with vigorous exercise.</effect>
+* <effect slug="withdrawal" label="Withdrawal / "crash"">Fatigue, depression, hypersomnia, increased appetite on abrupt discontinuation.</effect>
 | contraindications = * Hypersensitivity to amphetamines
 * Concurrent MAOI use, or within 14 days of MAOI discontinuation

MDElliottMD (talk | contribs)